KPTI Karyopharm Therapeutics Inc

Price (delayed)

$7.41

Market cap

$167.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$16.16

Enterprise value

$307.64M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 18

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related ...

Highlights
The revenue has grown by 6% YoY and by 3.5% from the previous quarter
The company's gross profit rose by 6% YoY and by 3.6% QoQ
The EPS has plunged by 100% YoY but it has grown by 10% from the previous quarter
The equity has contracted by 29% YoY but it has grown by 9% from the previous quarter
KPTI's debt is up by 24% YoY
Karyopharm Therapeutics's quick ratio has decreased by 16% YoY

Key stats

What are the main financial stats of KPTI

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
4.51%
1 week
-22.08%
1 month
-18.75%
1 year
67.27%
YTD
0.68%
QTD
-24.16%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$151.12M
Gross profit
$145.13M
Operating income
-$84.21M
Net income
-$194.97M
Gross margin
96%
Net margin
-129%
KPTI's net margin has plunged by 193% YoY but it is up by 3.9% from the previous quarter
KPTI's operating margin is up by 33% YoY and by 10% QoQ
KPTI's operating income is up by 29% YoY and by 7% QoQ
The revenue has grown by 6% YoY and by 3.5% from the previous quarter

Price vs fundamentals

How does KPTI's price correlate with its fundamentals

Growth

What is Karyopharm Therapeutics's growth rate over time

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.04
The EPS has plunged by 100% YoY but it has grown by 10% from the previous quarter
The equity has contracted by 29% YoY but it has grown by 9% from the previous quarter
The P/S is 116% higher than the last 4 quarters average of 0.5 but 17% lower than the 5-year quarterly average of 1.3
The revenue has grown by 6% YoY and by 3.5% from the previous quarter

Efficiency

How efficient is Karyopharm Therapeutics business performance
The ROS has grown by 5% from the previous quarter
Karyopharm Therapeutics's return on invested capital has decreased by 2.8% QoQ

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 67% smaller than its total liabilities
KPTI's total assets is up by 21% since the previous quarter and by 2.9% year-on-year
KPTI's total liabilities is up by 19% YoY
KPTI's debt is 187% more than its equity
The equity has contracted by 29% YoY but it has grown by 9% from the previous quarter
KPTI's debt is up by 24% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.